New inhaled treatment aims to save lungs and reduce ventilator time in ICU patients

NCT ID NCT07317050

Not yet recruiting Disease control Sponsor: Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether an inhaled drug called aprotinin can improve outcomes for adults with moderate to severe acute respiratory distress syndrome (ARDS), a life-threatening lung condition. About 156 critically ill patients in intensive care will receive either aprotinin or a placebo, alongside standard care. The main goal is to see if the drug helps patients spend more days off a ventilator and reduces the risk of death within 28 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hospital General Universitario de Ciudad Real

Ciudad Real, Ciudad Real, 13005, Spain

Contact Phone: •••-•••-•••• Email: •••••@•••••